These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33794484)

  • 21. Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography: Insights From the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Grundeken MJ; Nakatani S; Asano T; Sotomi Y; Foin N; Ng J; Okamura T; Wykrzykowska JJ; de Winter RJ; van Geuns RJ; Koolen J; Christiansen EH; Whitbourn R; McClean D; Smits P; Windecker S; Ormiston JA; Serruys PW
    Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28893770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
    Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Very late metallic stent malapposition and in-stent restenosis treated with a bioresorbable scaffold: a novel alternative for an old problem.
    Foin N; Lee R; Wong P; Low AF
    EuroIntervention; 2015 Aug; 11(4):e1. PubMed ID: 26298237
    [No Abstract]   [Full Text] [Related]  

  • 26. A Case of Single Coronary With Very Late In-Stent Restenosis of Drug-Eluting Stents After 12 Years.
    Vijayvergiya R; Kumar B; Budhakoty S; Kasinadhuni G; Kanabar K
    J Invasive Cardiol; 2019 Nov; 31(11):E333-E334. PubMed ID: 31671063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
    Gogas BD; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Bourantas CV; Serruys PW
    JACC Cardiovasc Interv; 2013 Mar; 6(3):211-21. PubMed ID: 23517830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-scaffold restenosis in a previous left main bifurcation lesion treated with bioresorbable scaffold v-stenting.
    Miyazaki T; Panoulas VF; Sato K; Kawamoto H; Naganuma T; Latib A; Colombo A
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):e7-e10. PubMed ID: 25499306
    [No Abstract]   [Full Text] [Related]  

  • 30. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One Year of OCT Follow-Up After Implantation of Three Different BRS in the Same Coronary Artery.
    Franzè A; Cerrato E; Rolfo C; Quadri G; Tomassini F; Varbella F
    Cardiovasc Revasc Med; 2020 Nov; 21(11S):121-122. PubMed ID: 32513605
    [No Abstract]   [Full Text] [Related]  

  • 32. Neoatherosclerosis as the Cause of Late Failure of a Bioresorbable Vascular Scaffold at 8 Months.
    Kang SH; Kang SJ; Kim WJ
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1896-1898. PubMed ID: 28866035
    [No Abstract]   [Full Text] [Related]  

  • 33. Migrated remnant bioresorbable scaffolds in a left main bifurcation lesion: Insights from optical coherence tomography.
    Seo J; Kim Y; Kim BK; Hong SJ; Ahn CM; Kim JS; Cho DK; Ko YG; Choi D; Hong MK; Jang Y
    Cardiol J; 2020; 27(2):208-209. PubMed ID: 32463107
    [No Abstract]   [Full Text] [Related]  

  • 34. An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer-coated sirolimus-eluting stents.
    Legutko J; Gil RJ; Buszman PE; Kaluza GL; Mintz GS; Roleder T; Krol M; Wojdyla R; Pawlowski T; Brzezinski M; Kondys M; Skwarna B; Jakala J; Zasada W; Partyka L; Dudek D
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):302-309. PubMed ID: 29027737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
    Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
    JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel.
    Naganuma T; Latib A; Ielasi A; Panoulas VF; Sato K; Miyazaki T; Colombo A
    Int J Cardiol; 2014 Apr; 172(3):618-9. PubMed ID: 24495653
    [No Abstract]   [Full Text] [Related]  

  • 37. Chronic Total Occlusion 5 Years After Bioresorbable Vascular Scaffold Implantation: A Serial Optical Coherence Tomography Assessment.
    Ochijewicz D; Tomaniak M; Kołtowski L; Kochman J
    J Invasive Cardiol; 2020 May; 32(5):E141. PubMed ID: 32357140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenging treatment of in-stent restenosis in a coronary bifurcation by implantation of a bioresorbable scaffold under optical coherence tomography guidance.
    Zuk G; Ciecwierz D; Drewla P; Gruchała M; Gutiérrez-Chico JL; Jaguszewski M
    Cardiol J; 2019; 26(3):304-306. PubMed ID: 31246271
    [No Abstract]   [Full Text] [Related]  

  • 39. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
    Vesga B; Hernandez H; Moncada M; Gasior P; Higuera S; Dager A; Arana C; Delgado JA; Généreux P; Maehara A; Granada JF
    Coron Artery Dis; 2017 Mar; 28(2):126-134. PubMed ID: 27879518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.